Pharmaceuticals

Atlanta lawyer Anne Tyler Hall lands on Inc.'s prestigious list for saving companies millions and mastering complex employee benefits law.

With its novel glaucoma drug QLS-111 entering Phase 3, Qlaris Bio brings in seasoned leader Fred Guerard to navigate the final trials and path to market.

Assets of pioneering engineering firm Xytel Corp. go to auction after its closure, offering rare deals on high-demand industrial equipment.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

Paperpal's new HIPAA-ready AI platform for life sciences offers secure data handling, aiming to accelerate research while ensuring regulatory compliance.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

A global consortium pioneers new drugs designed specifically for children, moving away from harsh adult treatments for aggressive pediatric cancers.

ViruSure's new GMP-validated test using Oxford Nanopore sequencing promises to slash drug safety testing times, boosting supply chain resilience.

Telehealth firm Direct Meds offers cheap GLP-1 drugs, but an FDA warning for "false claims" and the end of drug shortages cast a long shadow on its model.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

Emalex Biosciences offers its investigational drug ecopipam to Tourette syndrome patients out of options, signaling a potential shift in treatment.

A massive investment in Kankakee promises hundreds of jobs and a vital increase in life-saving plasma therapies for patients with rare diseases.

With 8x sales growth and 90% prediction accuracy, AI pioneer QuantHealth is proving that simulating clinical trials can slash pharma's $50B failure rate.

A new, highly selective drug for Duchenne muscular dystrophy shows potential to be safer and more effective, targeting both muscle and heart decline.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

A new drug, CRS3123, not only cures C. difficile but drastically cuts recurrence rates by preserving the gut microbiome, a major leap over standard care.

A new AI platform promises to solve the toxicology industry's capacity crisis, but can it win the trust of regulators and the scientists it’s meant to help?